Using explicit thresholds for benefits and harms in partially contextualized GRADE guidelines. Pilot experience from a living COVID-19 guideline

dc.contributor.authorNeumann, Ignacio
dc.contributor.authorQuiñelen, Eduardo
dc.contributor.authorNahuelhual, Paula
dc.contributor.authorBurdiles, Pamela
dc.contributor.authorCeledón, Natalia
dc.contributor.authorCerda, Katherine
dc.contributor.authorHerrera-Omegna, Paloma
dc.contributor.authorKraemer, Patricia
dc.contributor.authorCancino, Karen Dominguez
dc.contributor.authorValenzuela, Juan Pablo
dc.contributor.authorSepúlveda, Dino
dc.contributor.authorMorgano, Gian Paolo
dc.contributor.authorAkl, Elie A.
dc.contributor.authorSchunëmann, Holger J.
dc.contributor.departmentInternal Medicine
dc.contributor.facultyFaculty of Medicine (FM)
dc.contributor.institutionAmerican University of Beirut
dc.date.accessioned2025-01-24T11:44:26Z
dc.date.available2025-01-24T11:44:26Z
dc.date.issued2022
dc.description.abstractObjectives: Guideline panels must assess the magnitude of health benefits and harms to develop sensible recommendations. However, they rarely use explicit thresholds. In this paper we report on the piloting and the use thresholds for benefits and harms. Study Design and Setting: We piloted the use of thresholds in a Chilean COVID-19 living guideline. For each of the critical outcomes, we asked panelists to suggest values of the thresholds for large, moderate, small, or trivial or no effect. We collected this information through a survey and an on-line discussion. Results: Twelve panelists decided on thresholds for three critical outcomes (mortality, need for mechanical ventilation and serious adverse events). For all outcomes, an absolute risk reduction was considered larger with more than 50 events, moderate with less than 50 events, small with less than 25 events, and trivial with less than 10 events. Having these a priori thresholds in place significantly impacted on the development of recommendations. Conclusion: Explicit thresholds were a valuable addition to the judgment of the certainty in the evidence, to decide the direction and strength of the recommendation and to evaluate the need for update. We believe this is a line of research worth perusing. © 2022 Elsevier Inc.
dc.identifier.doihttps://doi.org/10.1016/j.jclinepi.2022.03.017
dc.identifier.eid2-s2.0-85129247343
dc.identifier.pmid35364230
dc.identifier.urihttp://hdl.handle.net/10938/30447
dc.language.isoen
dc.publisherElsevier Inc.
dc.relation.ispartofJournal of Clinical Epidemiology
dc.sourceScopus
dc.subjectClinical guidelines
dc.subjectCovid-19
dc.subjectGrade
dc.subjectChile
dc.subjectHumans
dc.subjectResearch report
dc.subjectBudesonide
dc.subjectColchicine
dc.subjectDexamethasone
dc.subjectRemdesivir
dc.subjectTocilizumab
dc.subjectArticle
dc.subjectArtificial ventilation
dc.subjectAssisted ventilation
dc.subjectClinical outcome
dc.subjectConflict of interest
dc.subjectCoronavirus disease 2019
dc.subjectDecision making
dc.subjectEmergency medicine
dc.subjectEvidence based practice
dc.subjectHealth care organization
dc.subjectHigh risk patient
dc.subjectHospital patient
dc.subjectHuman
dc.subjectInternal medicine
dc.subjectInvasive ventilation
dc.subjectLow risk patient
dc.subjectNoninvasive ventilation
dc.subjectPalliative therapy
dc.subjectPerceptive threshold
dc.subjectPractice guideline
dc.subjectRisk reduction
dc.subjectSystematic review (topic)
dc.subjectResearch
dc.titleUsing explicit thresholds for benefits and harms in partially contextualized GRADE guidelines. Pilot experience from a living COVID-19 guideline
dc.typeArticle

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
2022-1629.pdf
Size:
676.96 KB
Format:
Adobe Portable Document Format